This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy

Eli Lilly reported exceptional third-quarter results, with revenue surging 54% year-over-year to $17.6 billion and non-GAAP EPS increasing 495%, primarily driven by the strong performance of its tirzepatide franchise (Mounjaro and Zepbound). The company subsequently raised its fiscal year 2025 revenue guidance to $63-$63.5 billion, reflecting a projected 40.6% year-over-year growth at the midpoint. This robust performance is further bolstered by a promising pipeline in weight management, including the investigational oral GLP-1 orforglipron and the triple-acting retatrutide, alongside strategic advancements in oncology and a significant investment in AI for drug discovery, positioning Eli Lilly for sustained market leadership despite potential pricing adjustments for some products.

Analysis

Eli Lilly reported exceptional third-quarter results, with revenue surging 54% year-over-year to $17.6 billion and non-GAAP earnings per share increasing 495% to $7.02. This significant outperformance was primarily driven by its tirzepatide franchise (Mounjaro and Zepbound), which generated $10.1 billion in revenue, more than doubling from the prior period. Consequently, the company raised its fiscal year 2025 revenue guidance to $63 billion-$63.5 billion, implying a robust 40.6% year-over-year growth at the midpoint.

Future growth is further underpinned by a strong weight management pipeline, including the investigational oral GLP-1 orforglipron, which is on an expedited approval path for early next year. Additionally, retatrutide, a triple-acting gut hormone mimetic, shows potential for even deeper weight loss than tirzepatide, solidifying Eli Lilly's market dominance. The company also noted progress in oncology with Verzenio sales up 7% and the recent approval of Inluriyo.

Strategically, Eli Lilly is investing in long-term efficiency through a partnership with Nvidia to build an AI supercomputer, aiming to accelerate drug development and reduce costs. While a recent deal with the White House will lower Mounjaro and Zepbound prices for certain Medicare/Medicaid patients, the article suggests this impact will be mitigated by increased sales volume and limited eligibility, preventing a significant blow to the franchise.

Key Decisions for Investors

• Investors should consider maintaining or increasing exposure to Eli Lilly, given its exceptional Q3 performance, significantly raised guidance, and robust pipeline in high-growth therapeutic areas.
• Monitor the commercial launch and uptake of orforglipron and the clinical progression of retatrutide, as these represent significant future growth catalysts in the weight management market.
• Evaluate the actual financial impact of the Medicare/Medicaid pricing adjustments on Mounjaro and Zepbound sales volumes and profitability over the coming quarters, despite the article's optimistic assessment of mitigation.